Irvin William J, Carey Lisa A
Department of Medicine, Division of Hematology/Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599-7305, USA.
Eur J Cancer. 2008 Dec;44(18):2799-805. doi: 10.1016/j.ejca.2008.09.034. Epub 2008 Nov 12.
Triple-negative (ER-negative, PR-negative, HER2/neu not overexpressed) breast cancer has distinct clinical and pathologic features, and is a clinical problem because of its relatively poor prognosis, aggressive behaviour and lack of targeted therapies, leaving chemotherapy as the mainstay of treatment. Most triple-negative tumours fall into the basal-like molecular subtype of breast cancer, but the terms are not completely synonymous. Among the intriguing characteristics of triple-negative breast cancer is its association with cancers arising in BRCA1 mutation carriers, in young women and in African-American women. The reasons for these associations are unclear but may ultimately provide avenues for prevention and targeted therapy. This review discusses the definitions and characteristics of as well as current and evolving therapies for triple-negative and basal-like breast cancer.
三阴性（雌激素受体阴性、孕激素受体阴性、人表皮生长因子受体2/neu未过表达）乳腺癌具有独特的临床和病理特征，因其预后相对较差、侵袭性强且缺乏靶向治疗方法，化疗成为主要治疗手段，这是一个临床难题。大多数三阴性肿瘤属于乳腺癌的基底样分子亚型，但这两个术语并不完全同义。三阴性乳腺癌的有趣特征之一是它与携带BRCA1基因突变者、年轻女性以及非裔美国女性所患的癌症有关。这些关联的原因尚不清楚，但最终可能为预防和靶向治疗提供途径。本综述讨论了三阴性和基底样乳腺癌的定义、特征以及当前和不断发展的治疗方法。
